Format
Items per page
Sort by

Send to:

Choose Destination

Results: 18

References for PMC Articles for PubMed (Select 19172157)

1.

Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin.

Urban TJ, Brown C, Castro RA, Shah N, Mercer R, Huang Y, Brett CM, Burchard EG, Giacomini KM.

Clin Pharmacol Ther. 2008 Mar;83(3):416-21. Epub 2007 Jul 4.

PMID:
17609685
2.

Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics.

Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, Sheardown SA, Yue L, Burchard EG, Brett CM, Giacomini KM.

Clin Pharmacol Ther. 2008 Feb;83(2):273-80. Epub 2007 Jul 4.

3.

Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity.

Yokoo S, Yonezawa A, Masuda S, Fukatsu A, Katsura T, Inui K.

Biochem Pharmacol. 2007 Aug 1;74(3):477-87. Epub 2007 Mar 12.

PMID:
17582384
4.

Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters.

Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, Inui K.

Biochem Pharmacol. 2007 Jul 15;74(2):359-71. Epub 2007 Apr 13.

PMID:
17509534
5.

Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family.

Chen Y, Zhang S, Sorani M, Giacomini KM.

J Pharmacol Exp Ther. 2007 Aug;322(2):695-700. Epub 2007 May 10.

6.

Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action.

Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, Brett CM, Giacomini KM.

J Clin Invest. 2007 May;117(5):1422-31.

7.

Organic cation transporters are determinants of oxaliplatin cytotoxicity.

Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, Chen Y, Komori T, Gray JW, Chen X, Lippard SJ, Giacomini KM.

Cancer Res. 2006 Sep 1;66(17):8847-57.

8.
9.

Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2.

Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T, Ogawa O, Inui K.

J Am Soc Nephrol. 2006 Aug;17(8):2127-35. Epub 2006 Jun 28.

10.

Functional genomics of membrane transporters in human populations.

Urban TJ, Sebro R, Hurowitz EH, Leabman MK, Badagnani I, Lagpacan LL, Risch N, Giacomini KM.

Genome Res. 2006 Feb;16(2):223-30. Epub 2005 Dec 14.

11.

A human transporter protein that mediates the final excretion step for toxic organic cations.

Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y.

Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):17923-8. Epub 2005 Dec 5.

12.

The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics.

Erdman AR, Mangravite LM, Urban TJ, Lagpacan LL, Castro RA, de la Cruz M, Chan W, Huang CC, Johns SJ, Kawamoto M, Stryke D, Taylor TR, Carlson EJ, Ferrin TE, Brett CM, Burchard EG, Giacomini KM.

Am J Physiol Renal Physiol. 2006 Apr;290(4):F905-12. Epub 2005 Nov 15.

13.

Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations.

Gray JH, Mangravite LM, Owen RP, Urban TJ, Chan W, Carlson EJ, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, Giacomini KM.

Mol Pharmacol. 2004 Mar;65(3):512-9.

14.

Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1.

Shu Y, Leabman MK, Feng B, Mangravite LM, Huang CC, Stryke D, Kawamoto M, Johns SJ, DeYoung J, Carlson E, Ferrin TE, Herskowitz I, Giacomini KM; Pharmacogenetics Of Membrane Transporters Investigators.

Proc Natl Acad Sci U S A. 2003 May 13;100(10):5902-7. Epub 2003 Apr 28.

15.

Natural variation in human membrane transporter genes reveals evolutionary and functional constraints.

Leabman MK, Huang CC, DeYoung J, Carlson EJ, Taylor TR, de la Cruz M, Johns SJ, Stryke D, Kawamoto M, Urban TJ, Kroetz DL, Ferrin TE, Clark AG, Risch N, Herskowitz I, Giacomini KM; Pharmacogenetics Of Membrane Transporters Investigators.

Proc Natl Acad Sci U S A. 2003 May 13;100(10):5896-901. Epub 2003 Apr 28.

16.

Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function.

Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, Clark AG, Herskowitz I, Giacomini KM; Pharmacogenetics of Membrane Transporters Investigators.

Pharmacogenetics. 2002 Jul;12(5):395-405.

PMID:
12142729
17.

Genes in a refined Smith-Magenis syndrome critical deletion interval on chromosome 17p11.2 and the syntenic region of the mouse.

Bi W, Yan J, Stankiewicz P, Park SS, Walz K, Boerkoel CF, Potocki L, Shaffer LG, Devriendt K, Nowaczyk MJ, Inoue K, Lupski JR.

Genome Res. 2002 May;12(5):713-28.

18.

Interstitial deletion of (17)(p11.2p11.2) in nine patients.

Smith AC, McGavran L, Robinson J, Waldstein G, Macfarlane J, Zonona J, Reiss J, Lahr M, Allen L, Magenis E.

Am J Med Genet. 1986 Jul;24(3):393-414.

PMID:
2425619
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk